KPTI - カリョファ―ム・セラピュ―ティクス (Karyopharm Therapeutics Inc.) カリョファ―ム・セラピュ―ティクス

 KPTIのチャート


 KPTIの企業情報

symbol KPTI
会社名 Karyopharm Therapeutics Inc (カリョファ―ム・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 カリオファーム・セラピューティクス(Karyopharm Therapeutics Inc.)は臨床段階の製薬会社である。同社はその他の主要疾患と癌の治療用核輸送と関連ターゲットに対する薬物の発見・開発・商業化に焦点を当てる。同社は核輸出タンパク質XPO1を阻害する化合物、核輸出の選択的阻害剤(SINE)及び小分子を発見・開発する。同社の薬物候補であるセリネクサー(KPT-330)は前処理再発性のがん徴候の治療のための経口投与剤である。同社はまた固形腫瘍適応症におけるセリクソーの臨床開発に従事する。口腔セリソクサーは再発性・難治性血液学と固形腫瘍の悪性腫瘍患者に行われる複数の後期臨床試験で評価される。リード薬候補である口腔セリソクサー(KPT-330)、verdinexor(KPT-335)、KPT-8602およびKPT-9274は臨床開発中である。   カリョファ―ム・セラピュ―ティクスは米国の製薬会社。がんや他の主要疾患の新治療薬の発見・開発に従事。主な製品候補には、臨床段階の多発性骨髄腫治療薬「セリネクソ―ル」がある。また、白血病などの治療薬候補も保有。同社は2008年に設立し、マサチュ―セッツ州に本社を置く。   Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIO® (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade® (bortezomib) and dexamethasone for the treatment of patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for NEXPOVIO® (selinexor) for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.
本社所在地 85 Wells Avenue 2nd Floor Newton MA 02459 USA
代表者氏名 Sharon Shacham シャロン・シャチャム
代表者役職名 President Co-Founder Chief Scientific Officer
電話番号 +1 617-658-0600
設立年月日 39783
市場名 NASDAQ National Market System
ipoyear 2013年
従業員数 154人
url www.karyopharm.com
nasdaq_url https://www.nasdaq.com/symbol/kpti
adr_tso
EBITDA EBITDA(百万ドル) -143.07800
終値(lastsale) 15.55
時価総額(marketcap) 941761631.95
時価総額 時価総額(百万ドル) 743.11350
売上高 売上高(百万ドル) 31.42500
企業価値(EV) 企業価値(EV)(百万ドル) 501.99250
当期純利益 当期純利益(百万ドル) -141.79400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Karyopharm Therapeutics Inc revenues increased from $71K to $29.9M. Net loss increased 22% to $72.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and Development increase of 82% to $86.1M (expense) General and Administrative increase of 33% to $17.1M (expense).

 KPTIのテクニカル分析


 KPTIのニュース

   FY2021 EPS Estimates for Karyopharm Therapeutics Inc. Boosted by Wedbush (NASDAQ:KPTI)  2021/12/24 11:58:41 Transcript Daily
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Investment analysts at Wedbush upped their FY2021 earnings per share (EPS) estimates for shares of Karyopharm Therapeutics in a note issued to investors on Tuesday, December 21st. Wedbush analyst D. Nierengarten now expects that the company will earn ($1.81) per share for the year, up from their prior estimate of []
   Karyopharm, Menarini Ink Over $200M Licensing Pact For Selinexor In Europe, Other Territories  2021/12/21 20:09:57 Benzinga
Karyopharm Therapeutics Inc (NASDAQ: KPTI ) and the Menarini Group entered an exclusive licensing agreement whereby Menarini will commercialize Karyopharm''s Nexpovio (selinexor) in Europe and other key global territories. Under the agreement terms, Menarini received exclusive rights to commercialize Nexpovio for oncology indications in the European Union and other European countries, Latin America Full story available on Benzinga.com
   Is Karyopharm Therapeutics Inc. (NASDAQ: KPTI) A Great Stock To Invest In?  2021/12/21 18:00:00 Stocks Register
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) traded at $6.47 at last check on Tuesday, December 21, made an upward move of 1.65% on its previous day’s price. Looking at the stock we see that its previous close was $6.36 and the beta (5Y monthly) reads 0.20 with the day’s price range being $5.88 – $6.48. In terms … Is Karyopharm Therapeutics Inc. (NASDAQ: KPTI) A Great Stock To Invest In? Read More »
   Karyopharm Therapeutics Inc. (KPTI) Gains 3.41%, Causing Bears To Win  2021/12/21 13:30:00 Marketing Sentinel
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has a beta value of -0.03 and has seen 1.79 million shares traded in the last trading session. The company, currently valued at $468.80M, closed the last trade at $6.36 per share which meant it gained $0.21 on the day or 3.41% during that session. The KPTI stock price is -183.02% … Karyopharm Therapeutics Inc. (KPTI) Gains 3.41%, Causing Bears To Win Read More »
   Brokerages Expect Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Will Post Quarterly Sales of $29.61 Million  2021/12/20 09:20:41 Dakota Financial News
Brokerages expect Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to announce sales of $29.61 million for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Karyopharm Therapeutics earnings, with the lowest sales estimate coming in at $24.30 million and the highest estimate coming in at $38.69 million. Karyopharm Therapeutics posted sales of $35.10 million []
   Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Forecasted to Post FY2021 Earnings of ($2.88) Per Share  2021/11/09 07:38:42 Transcript Daily
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Equities research analysts at SVB Leerink reduced their FY2021 earnings per share estimates for Karyopharm Therapeutics in a report issued on Wednesday, November 3rd. SVB Leerink analyst J. Chang now forecasts that the company will earn ($2.88) per share for the year, down from their prior estimate of ($2.86). SVB []
   Karyopharm Therapeutics Inc. 2021 Q3 - Results - Earnings Call Presentation  2021/11/08 13:22:46 Seeking Alpha
   Karyopharm rises as selinexor shows benefit in myelofibrosis in phase 2 interim data  2021/11/04 16:22:58 Seeking Alpha
   Karyopharm Therapeutics Sees Unusually Large Options Volume (NASDAQ:KPTI)  2021/11/04 13:52:42 Dakota Financial News
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was the target of some unusual options trading activity on Wednesday. Stock investors bought 13,436 call options on the company. This represents an increase of 1,703% compared to the average daily volume of 745 call options. Several hedge funds and other institutional investors have recently bought and sold shares of the []
   KPTI, FGF and EVAX among mid-day movers  2021/11/03 18:12:15 Seeking Alpha
   Karyopharm Therapeutics (KPTI) Investor Presentation - Slideshow  2021/09/16 19:27:55 Seeking Alpha
   Karyopharm Therapeutics: After Years Of Waiting I''m Ready To Join The Bulls  2021/09/16 01:28:50 Seeking Alpha
   Global Pet Cancer Therapeutics Market Size, Trends and Forecast 2027 By | Karyopharm Therapeutics, Inc., Zoetis  2021/08/24 13:58:26 OpenPR
The Pet Cancer Therapeutics Market study provides a thorough but completes analysis of the worldwide Pet Cancer Therapeutics market, including all of the major company profiles that have an impact on the market''s growth and breadth. The study is written
   Rubric Capital Management LP Buys Golar LNG, Arconic Corp, Karyopharm Therapeutics Inc, Sells ...  2021/08/17 18:38:09 GuruFocus
Related Stocks: OCUL , TROX , PTVE , PLYA , MORF , RDUS , GLNG , ARNC , KPTI , HMHC , CHMA , HSC , RXT , APO , MIC , THC , USFD , AEL ,
   Cramer Shares His Thoughts On Moderna, Nvidia And More  2021/08/13 11:31:18 Business Insider Markets
On CNBC''s "Mad Money Lightning Round," Jim Cramer said Karyopharm Therapeutics Inc (NASDAQ: KPTI ) is nothing special. Cramer likes Iron Mountain Inc (NYSE: IRM ).

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 カリョファ―ム・セラピュ―ティクス KPTI Karyopharm Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)